New Delhi: Bharat Biotech’s Covaxin is effective against the UK variant of the virus. Taking to Twitter, Bharat Biotech said “Covaxin effectively neutralises UK variants of SARS-CoV-2 reducing the possibility of mutant virus escape”. The tweet also enclosed a link to a report of its research findings. However, the study is yet to be peer-reviewed, ZeeNews reported.
The UK variant of the virus is considered to be 70 percent more infectious and more lethal than Wuhan one. In India, 150 cases of the UK strain have been reported.
Covaxin was approved for emergency use by the drug regulatory authority in January. The regulator, however, said the vaccine’s use will be in the clinical trial mode, which means all its recipients will be tracked and monitored, the report added.
